You've chosen Americas as your location.

To clear your location selection and return to IPS Global, click below.

Return to IPS Global

You've chosen Americas as your location.

Thank you for choosing a location. This will help us show you the information that matters the most to you.

Continue Change Selection
Insights

Should it be Scale-Up or Scale Out… Bigger is Not Always Better or Faster

Mar 01, 2012

Insights

Should it be Scale-Up or Scale Out… Bigger is Not Always Better or Faster

Mar 01, 2012

In the current environment, the pharmaceutical technologist is faced with an ever changing series of regulations, difficult to process drug substances and the time to make market entry and reach maximum product potential.

For many drug substance candidates, the inherent physicochemical and pharmacokinetic properties pose unique challenges necessitating the application of advanced solid dosage form technologies.

The same is true for innovators as well as generic firms that are manufacturing bioavailable products; which are seamlessly reviewed and reach the market quickly. Imbedded in this technical tapestry is the inevitable question of how large a batch needs to be, or more fundamentally, ‘what scale do I need to achieve?’. In many cases, the need for scaleup and the effort to achieve this are looked at as a major technical challenge.

To read more go to http://ipsdb.com/pdfs/IPS_Technologies_Tours.pdf#page=10"

Related Experts

Related Expertise

Choose Your Location

To customize your experience, select an IPS region or country to view specific information based on your location.

  • Americas
  • United States
  • Canada
  • Brazil
  • All Other Countries

You’ve chosen as your location.

Thank you for choosing a location. This will help us show the information that means to most to you. Continue to the homepage to view featured projects, and happenings specific to your location.

Continue